1. Lyseng-Williamson KA, Perry CM: Drotrecogin alfa (activated). Drugs. 2002, 62: 617-30. 10.2165/00003495-200262040-00006. discussion 631-2
2. Food and Drug Administration: FDA Clinical Review. Drotrecogin alfa (activated). [Recombinant human activated protein C (rhAPC)] XIGRIS (TM). 2001, Last access: August 2006, [ http://www.fda.gov/cder/biologics/review/droteli112101r1.pdf ] . Parts 1 and 2
3. United States Food and Drug Administration. Drotrecogin alfa (activated) letter of approval. November 21st 2001. Last access: July 2006, [ http://www.fda.gov/cder/foi/appletter/2001/droteli112101L.pdf ]
4. European Medicines Agency. Xigris product information. [ http://www.emea.eu.int/humandocs/Humans/EPAR/xigris/Xigris.htm ]
5. Health Canada. Notice of Compliance - Xigris - 31-01-2003. Last access: July 2006, [ http://www.nocdatabase.ca/ ]